Pedro Otavio de Campos Lima

• Abstract

  The research carried out in Experimental Oncology has a strong demand for animal tumor models. In parallel, the growing use of omics technologies generates a considerable volume of data, whose analysis and digital storage become a constant challenge. The resources from the institutional technical reserve will be directed to the infrastructure of the Boldrini Research Center, which concent…

  Support for the Animal Experimentation Unit and increase in the computational capacity of the Boldrini Research Center, AP.RT.INST

• Abstract

  Real-time access to the internet and intranet are essential for instrumental monitoring, data management, and information sharing between laboratories and supporting analytical platforms. The requested resources will be used to acquire equipment to improve the connectivity of the data network, in order to allow access by all laboratories of the Boldrini Research Center, which concentrates…

  Implementation of access to the Wi-Fi network in the laboratories and Animal Experimentation Unit of the Boldrini Research Center, AP.RT.REDNESP

• Abstract

  The immune system has the ability to recognize damage-associated molecular patterns (DAMPs) generated by tumor growth, which can lead to its elimination or continued inflammation. The initial innate immune response sets the stage for a specific adaptive immune reaction that is equipped to eradicate the neoplastic lesion, and often happens long before the disease becomes clinically detecta…

  Implications of adaptive immune response modulation in cancer control, AP.R

(Only some records are available in English at this moment)

• Abstract

  Acute lymphoblastic leukemia (ALL) is the most common cancer in children, representing 31% of all tumors. The conventional treatment of pediatric ALL is based on chemotherapeutic protocols that have shown good results with cure rates close to 80-90%. Despite this, 10-20% of children fail to respond to first-line therapy as well as have disease recurrence. The immunotherapy with geneticall…

  Engineering of T lymphocytes for the recognition of Acute Lymphoblastic Leukemia., BP.DR